These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

366 related articles for article (PubMed ID: 23803961)

  • 1. Use of 13-valent pneumococcal conjugate vaccine and 23-valent pneumococcal polysaccharide vaccine among children aged 6-18 years with immunocompromising conditions: recommendations of the Advisory Committee on Immunization Practices (ACIP).
    Centers for Disease Control and Prevention (CDC)
    MMWR Morb Mortal Wkly Rep; 2013 Jun; 62(25):521-4. PubMed ID: 23803961
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Use of 13-valent pneumococcal conjugate vaccine and 23-valent pneumococcal polysaccharide vaccine for adults with immunocompromising conditions: recommendations of the Advisory Committee on Immunization Practices (ACIP).
    Centers for Disease Control and Prevention (CDC)
    MMWR Morb Mortal Wkly Rep; 2012 Oct; 61(40):816-9. PubMed ID: 23051612
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prevention of pneumococcal disease among infants and children - use of 13-valent pneumococcal conjugate vaccine and 23-valent pneumococcal polysaccharide vaccine - recommendations of the Advisory Committee on Immunization Practices (ACIP).
    Nuorti JP; Whitney CG;
    MMWR Recomm Rep; 2010 Dec; 59(RR-11):1-18. PubMed ID: 21150868
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Use of 13-valent pneumococcal conjugate vaccine and 23-valent pneumococcal polysaccharide vaccine among adults aged ≥65 years: recommendations of the Advisory Committee on Immunization Practices (ACIP).
    Tomczyk S; Bennett NM; Stoecker C; Gierke R; Moore MR; Whitney CG; Hadler S; Pilishvili T;
    MMWR Morb Mortal Wkly Rep; 2014 Sep; 63(37):822-5. PubMed ID: 25233284
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Licensure of a 13-valent pneumococcal conjugate vaccine (PCV13) and recommendations for use among children - Advisory Committee on Immunization Practices (ACIP), 2010.
    Centers for Disease Control and Prevention (CDC)
    MMWR Morb Mortal Wkly Rep; 2010 Mar; 59(9):258-61. PubMed ID: 20224542
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Use of 13-Valent Pneumococcal Conjugate Vaccine and 23-Valent Pneumococcal Polysaccharide Vaccine Among Adults Aged ≥65 Years: Updated Recommendations of the Advisory Committee on Immunization Practices.
    Matanock A; Lee G; Gierke R; Kobayashi M; Leidner A; Pilishvili T
    MMWR Morb Mortal Wkly Rep; 2019 Nov; 68(46):1069-1075. PubMed ID: 31751323
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Intervals Between PCV13 and PPSV23 Vaccines: Recommendations of the Advisory Committee on Immunization Practices (ACIP).
    Kobayashi M; Bennett NM; Gierke R; Almendares O; Moore MR; Whitney CG; Pilishvili T
    MMWR Morb Mortal Wkly Rep; 2015 Sep; 64(34):944-7. PubMed ID: 26334788
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Licensure of 13-valent pneumococcal conjugate vaccine for adults aged 50 years and older.
    Centers for Disease Control and Prevention (CDC)
    MMWR Morb Mortal Wkly Rep; 2012 Jun; 61(21):394-5. PubMed ID: 22647745
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pneumococcal Vaccination Among Medicare Beneficiaries Occurring After the Advisory Committee on Immunization Practices Recommendation for Routine Use Of 13-Valent Pneumococcal Conjugate Vaccine and 23-Valent Pneumococcal Polysaccharide Vaccine for Adults Aged ≥65 Years.
    Black CL; Williams WW; Warnock R; Pilishvili T; Kim D; Kelman JA
    MMWR Morb Mortal Wkly Rep; 2017 Jul; 66(27):728-733. PubMed ID: 28704347
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Preventing pneumococcal disease among infants and young children. Recommendations of the Advisory Committee on Immunization Practices (ACIP).
    Advisory Committee on Immunization Practices
    MMWR Recomm Rep; 2000 Oct; 49(RR-9):1-35. PubMed ID: 11055835
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Use of 15-Valent Pneumococcal Conjugate Vaccine Among U.S. Children: Updated Recommendations of the Advisory Committee on Immunization Practices - United States, 2022.
    Kobayashi M; Farrar JL; Gierke R; Leidner AJ; Campos-Outcalt D; Morgan RL; Long SS; Poehling KA; Cohen AL; ;
    MMWR Morb Mortal Wkly Rep; 2022 Sep; 71(37):1174-1181. PubMed ID: 36107786
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cost-effectiveness of administering 13-valent pneumococcal conjugate vaccine in addition to 23-valent pneumococcal polysaccharide vaccine to adults with immunocompromising conditions.
    Cho BH; Stoecker C; Link-Gelles R; Moore MR
    Vaccine; 2013 Dec; 31(50):6011-21. PubMed ID: 24148572
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Use of 15-Valent Pneumococcal Conjugate Vaccine and 20-Valent Pneumococcal Conjugate Vaccine Among U.S. Adults: Updated Recommendations of the Advisory Committee on Immunization Practices - United States, 2022.
    Kobayashi M; Farrar JL; Gierke R; Britton A; Childs L; Leidner AJ; Campos-Outcalt D; Morgan RL; Long SS; Talbot HK; Poehling KA; Pilishvili T
    MMWR Morb Mortal Wkly Rep; 2022 Jan; 71(4):109-117. PubMed ID: 35085226
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Immunogenicity and safety of a 13-valent pneumococcal conjugate vaccine in adults 70 years of age and older previously vaccinated with 23-valent pneumococcal polysaccharide vaccine.
    Jackson LA; Gurtman A; Rice K; Pauksens K; Greenberg RN; Jones TR; Scott DA; Emini EA; Gruber WC; Schmoele-Thoma B
    Vaccine; 2013 Aug; 31(35):3585-93. PubMed ID: 23688527
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Recent Developments and Future Directions of Pneumococcal Vaccine Recommendations.
    Tromp KM; Campbell MW; Vazquez A
    Clin Ther; 2015 May; 37(5):928-34. PubMed ID: 25913921
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Why the recent ACIP recommendations regarding conjugate pneumococcal vaccine in adults may be irrelevant.
    Musher DM; Rodriguez-Barradas MB
    Hum Vaccin Immunother; 2016; 12(2):331-5. PubMed ID: 26606172
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Influence of initial vaccination with 13-valent pneumococcal conjugate vaccine or 23-valent pneumococcal polysaccharide vaccine on anti-pneumococcal responses following subsequent pneumococcal vaccination in adults 50 years and older.
    Jackson LA; Gurtman A; van Cleeff M; Frenck RW; Treanor J; Jansen KU; Scott DA; Emini EA; Gruber WC; Schmoele-Thoma B
    Vaccine; 2013 Aug; 31(35):3594-602. PubMed ID: 23688525
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Uptake of 13-Valent Pneumococcal Conjugate Vaccine among US Adults Aged 19 to 64 Years with Immunocompromising Conditions.
    Vietri J; Harnett J; Emir B; Chilson E
    Hum Vaccin Immunother; 2020; 16(1):161-168. PubMed ID: 31343949
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Use of 21-Valent Pneumococcal Conjugate Vaccine Among U.S. Adults: Recommendations of the Advisory Committee on Immunization Practices - United States, 2024.
    Kobayashi M; Leidner AJ; Gierke R; Farrar JL; Morgan RL; Campos-Outcalt D; Schechter R; Poehling KA; Long SS; Loehr J; Cohen AL
    MMWR Morb Mortal Wkly Rep; 2024 Sep; 73(36):793-798. PubMed ID: 39264843
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pneumococcal Vaccine for Adults Aged ≥19 Years: Recommendations of the Advisory Committee on Immunization Practices, United States, 2023.
    Kobayashi M; Pilishvili T; Farrar JL; Leidner AJ; Gierke R; Prasad N; Moro P; Campos-Outcalt D; Morgan RL; Long SS; Poehling KA; Cohen AL
    MMWR Recomm Rep; 2023 Sep; 72(3):1-39. PubMed ID: 37669242
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 19.